Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Alzinova: Innovative new approach to Alzheimer’s - Edison

Alzinova

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Alzinova is a Sweden-based clinical-stage biopharmaceutical company seeking to advance treatments for Alzheimer’s disease (AD) via protein modification and immunotherapy-based solutions. Alzinova’s novel AβCC Peptide Technology is designed to target neurotoxic proteins with immunotherapy. The company’s pipeline consists of two oligomer-targeting immunotherapies – ALZ-101 (approaching Phase II) and ALZ-201 (preclinical) – with the latter being a more specific, preclinical-stage revision of ALZ-101. Phase Ib clinical trial results for ALZ-101 have shown good safety and tolerability and exploratory analysis of the efficacy of the drug exceeded expectations. ALZ-101 has been submitted for a Phase II clinical study seeking further evidence of the drug’s efficacy as an AD treatment in a larger patient group.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.